Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1985 Nov-Dec;58(6):579–596.

Peptide neuroregulators: the opioid system as a model.

J D Barchas, C Evans, G R Elliott, P A Berger
PMCID: PMC2589971  PMID: 2938344

Abstract

Aaron Lerner's work provides a stunning set of examples of substances that help to transmit information in the brain and body. His characterization of alpha-MSH and melatonin and his sparking of interest in the further discovery of previously unknown substances have been of inestimable value for the field of neurobiology. Efforts such as those that Lerner undertook so successfully in the field of investigative dermatology now constitute a major research thrust in the field of behavioral neurochemistry and are directly related to advances in psychiatry and neurology. This review considers aspects of research on the neuropeptides, with particular attention to the endogenous opioid (morphine-like) peptides that are active on neural tissue. Neuropeptide research can be categorized broadly as efforts to discover and characterize new families and classes of active agents, investigations of their genetic and molecular processing, and studies of their relationships to behavior in animals and human beings. This review selectively considers some key research questions and strategies that arise from such research.

Full text

PDF
579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akil H., Hewlett W. A., Barchas J. D., Li C. H. Binding of 3H-beta-endorphin to rat brain membranes: characterization of opiate properties and interaction with ACTH. Eur J Pharmacol. 1980 May 30;64(1):1–8. doi: 10.1016/0014-2999(80)90363-5. [DOI] [PubMed] [Google Scholar]
  2. Akil H., Watson S. J., Barchas J. D., Li C. H. B-ETA-Endorphin immunoreactivity in rat and human blood: radioimmunoassay, comparative levels and physiological alterations. Life Sci. 1979 Apr 30;24(18):1659–1665. doi: 10.1016/0024-3205(79)90250-9. [DOI] [PubMed] [Google Scholar]
  3. Akil H., Young E., Watson S. J., Coy D. H. Opiate binding properties of naturally occurring N- and C-terminus modified beta-endorphins. Peptides. 1981 Fall;2(3):289–292. doi: 10.1016/s0196-9781(81)80121-0. [DOI] [PubMed] [Google Scholar]
  4. Alexopoulos G. S., Inturrisi C. E., Lipman R., Frances R., Haycox J., Dougherty J. H., Jr, Rossier J. Plasma immunoreactive beta-endorphin levels in depression. Effect of electroconvulsive therapy. Arch Gen Psychiatry. 1983 Feb;40(2):181–183. doi: 10.1001/archpsyc.1983.01790020079007. [DOI] [PubMed] [Google Scholar]
  5. BARCHAS J. D., LERNER A. B. LOCALIZATION OF MELATONIN IN THE NERVOUS SYSTEM. J Neurochem. 1964 Jun;11:489–491. doi: 10.1111/j.1471-4159.1964.tb11608.x. [DOI] [PubMed] [Google Scholar]
  6. Barchas J. D., Akil H., Elliott G. R., Holman R. B., Watson S. J. Behavioral neurochemistry: neuroregulators and behavioral states. Science. 1978 May 26;200(4344):964–973. doi: 10.1126/science.25486. [DOI] [PubMed] [Google Scholar]
  7. Barchas J. D., Sullivan S. Opioid peptides as neuroregulators: potential areas for the study of genetic-behavioral mechanisms. Behav Genet. 1982 Feb;12(1):69–91. doi: 10.1007/BF01065741. [DOI] [PubMed] [Google Scholar]
  8. Berger P. A., Akil H., Watson S. J., Barchas J. D. Behavioral pharmacology of the endorphins. Annu Rev Med. 1982;33:397–415. doi: 10.1146/annurev.me.33.020182.002145. [DOI] [PubMed] [Google Scholar]
  9. Berger P. A., Barchas J. D. Studies of beta-endorphin in psychiatric patients. Ann N Y Acad Sci. 1982;398:448–459. doi: 10.1111/j.1749-6632.1982.tb39516.x. [DOI] [PubMed] [Google Scholar]
  10. Berger P. A. Investigating the role of endogenous opioid peptides in psychiatric disorders. Neurosci Res Program Bull. 1978 Dec;16(4):585–599. [PubMed] [Google Scholar]
  11. Berger P. A. Medical treatment of mental illness. Science. 1978 May 26;200(4344):974–981. doi: 10.1126/science.25487. [DOI] [PubMed] [Google Scholar]
  12. Berger P. A., Watson S. J., Akil H., Barchas J. D. The effects of naloxone in chronic schizophrenia. Am J Psychiatry. 1981 Jul;138(7):913–918. doi: 10.1176/ajp.138.7.913. [DOI] [PubMed] [Google Scholar]
  13. Berger P. A., Watson S. J., Akil H., Elliott G. R., Rubin R. T., Pfefferbaum A., Davis K. L., Barchas J. D., Li C. H. beta-Endorphin and schizophrenia. Arch Gen Psychiatry. 1980 Jun;37(6):635–640. doi: 10.1001/archpsyc.1980.01780190033003. [DOI] [PubMed] [Google Scholar]
  14. Boarder M. R., Erdelyi E., Barchas J. D. Synthetic N-dimethyl beta-endorphin, a stabilized opioid peptide. Biochem Pharmacol. 1981 Jun 1;30(11):1289–1293. doi: 10.1016/0006-2952(81)90311-7. [DOI] [PubMed] [Google Scholar]
  15. Boarder M. R., Weber E., Evans C. J., Erdelyi E., Barchas J. Measurement of total opioid peptides in rat brain and pituitary by radioimmunoassay directed at the alpha-N-acetyl derivative. J Neurochem. 1983 Jun;40(6):1517–1522. doi: 10.1111/j.1471-4159.1983.tb08120.x. [DOI] [PubMed] [Google Scholar]
  16. Brambilla F., Genazzani A. R., Facchinetti F., Parrini D., Petraglia F., Sacchetti E., Scarone S., Gustalla A., D'Antona N. beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders. Psychoneuroendocrinology. 1981 Dec;6(4):321–330. doi: 10.1016/0306-4530(81)90017-2. [DOI] [PubMed] [Google Scholar]
  17. Cohen M. R., Pickar D., Extein I., Gold M. S., Sweeney D. R. Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression. Am J Psychiatry. 1984 May;141(5):628–632. doi: 10.1176/ajp.141.5.628. [DOI] [PubMed] [Google Scholar]
  18. Cone R. I., Weber E., Barchas J. D., Goldstein A. Regional distribution of dynorphin and neo-endorphin peptides in rat brain, spinal cord, and pituitary. J Neurosci. 1983 Nov;3(11):2146–2152. doi: 10.1523/JNEUROSCI.03-11-02146.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Corbett A. D., Paterson S. J., McKnight A. T., Magnan J., Kosterlitz H. W. Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor. Nature. 1982 Sep 2;299(5878):79–81. doi: 10.1038/299079a0. [DOI] [PubMed] [Google Scholar]
  20. Davis G. C., Buchsbaum M. S., van Kammen D. P., Bunney W. E., Jr Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry Res. 1979 Jul;1(1):61–69. doi: 10.1016/0165-1781(79)90029-5. [DOI] [PubMed] [Google Scholar]
  21. Davis G. C., Bunney W. E., Jr, DeFraites E. G., Kleinman J. E., van Kammen D. P., Post R. M., Wyatt R. J. Intravenous naloxone administration in schizophrenia and affective illness. Science. 1977 Jul 1;197(4298):74–77. doi: 10.1126/science.325650. [DOI] [PubMed] [Google Scholar]
  22. Domschke W., Dickschas A., Mitznegg P. C.S.F. beta-endorphin in schizophrenia. Lancet. 1979 May 12;1(8124):1024–1024. doi: 10.1016/s0140-6736(79)92769-7. [DOI] [PubMed] [Google Scholar]
  23. Dysken M. W., Davis J. M. Naxolone in amylobarbitone-responsive catatonia. Br J Psychiatry. 1978 Nov;133:476–476. doi: 10.1192/bjp.133.5.476. [DOI] [PubMed] [Google Scholar]
  24. Eberwine J. H., Roberts J. L. Analysis of pro-opiomelancortin gene structure and function. DNA. 1983;2(1):1–8. doi: 10.1089/dna.1.1983.2.1. [DOI] [PubMed] [Google Scholar]
  25. Emrich H. M., Cording C., Pirée S., Kölling A., von Zerssen D., Herz A. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatr Neuropsychopharmakol. 1977 Sep;10(5):265–270. doi: 10.1055/s-0028-1094547. [DOI] [PubMed] [Google Scholar]
  26. Emrich H. M., Höllt V., Kissling W., Fischler M., Laspe H., Heinemann H., von Zerssen D., Herz A. beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmakopsychiatr Neuropsychopharmakol. 1979 May;12(3):269–276. doi: 10.1055/s-0028-1094620. [DOI] [PubMed] [Google Scholar]
  27. Emrich H. M., Kissling W., Fischler M., Zerssen D. V., Riedhammer H., Edel H. H. Hemodialysis in schizophrenia: three failures with chronic patients. Am J Psychiatry. 1979 Aug;136(8):1095–1095. doi: 10.1176/ajp.136.8.1095b. [DOI] [PubMed] [Google Scholar]
  28. Emrich H. M., Zaudig M., Kissling W., Dirlich G., von Zerssen D., Herz A. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients. Pharmakopsychiatr Neuropsychopharmakol. 1980 Sep;13(5):290–298. doi: 10.1055/s-2007-1019647. [DOI] [PubMed] [Google Scholar]
  29. Emrich H. M., Zaudig M., v Zerssen D., Herz A., Kissling W. Des-Tyr1-gamma-endorphin in schizophrenia. Lancet. 1980 Dec 20;2(8208-8209):1364–1365. doi: 10.1016/s0140-6736(80)92423-x. [DOI] [PubMed] [Google Scholar]
  30. Evans C. J., Erdelyi E., Weber E., Barchas J. D. Identification of pro-opiomelanocortin-derived peptides in the human adrenal medulla. Science. 1983 Sep 2;221(4614):957–960. doi: 10.1126/science.6308766. [DOI] [PubMed] [Google Scholar]
  31. Evans C. J., Lorenz R., Weber E., Barchas J. D. Variants of alpha-melanocyte stimulating hormone in rat brain and pituitary evidence that acetylated alpha-MSH exists only in the intermediate lobe of pituitary. Biochem Biophys Res Commun. 1982 Jun 15;106(3):910–919. doi: 10.1016/0006-291x(82)91797-1. [DOI] [PubMed] [Google Scholar]
  32. Evans C. J., Weber E., Barchas J. D. Isolation and characterization of alpha-N-acetyl beta-endorphin(1-26) from the rat posterior/intermediate pituitary lobe. Biochem Biophys Res Commun. 1981 Oct 15;102(3):897–904. doi: 10.1016/0006-291x(81)91622-3. [DOI] [PubMed] [Google Scholar]
  33. Gee C. E., Chen C. L., Roberts J. L., Thompson R., Watson S. J. Identification of proopiomelanocortin neurones in rat hypothalamus by in situ cDNA-mRNA hybridization. Nature. 1983 Nov 24;306(5941):374–376. doi: 10.1038/306374a0. [DOI] [PubMed] [Google Scholar]
  34. Gerner R. H., Catlin D. H., Gorelick D. A., Hui K. K., Li C. H. beta-Endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980 Jun;37(6):642–647. doi: 10.1001/archpsyc.1980.01780190040005. [DOI] [PubMed] [Google Scholar]
  35. Goldstein A., Fischli W., Lowney L. I., Hunkapiller M., Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7219–7223. doi: 10.1073/pnas.78.11.7219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Grau J. W., Hyson R. L., Maier S. F., Madden J., 4th, Barchas J. D. Long-term stress-induced analgesia and activation of the opiate system. Science. 1981 Sep 18;213(4514):1409–1411. doi: 10.1126/science.7268445. [DOI] [PubMed] [Google Scholar]
  37. Guidotti A., Forchetti C. M., Corda M. G., Konkel D., Bennett C. D., Costa E. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3531–3535. doi: 10.1073/pnas.80.11.3531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Gunne L. M., Lindström L., Terenius L. Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm. 1977;40(1):13–19. doi: 10.1007/BF01250276. [DOI] [PubMed] [Google Scholar]
  39. HARRIS J. I., LERNER A. B. Amino-acid sequence of the alpha-melanocyte-stimulating hormone. Nature. 1957 Jun 29;179(4574):1346–1347. doi: 10.1038/1791346a0. [DOI] [PubMed] [Google Scholar]
  40. Hughes J., Smith T. W., Kosterlitz H. W., Fothergill L. A., Morgan B. A., Morris H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975 Dec 18;258(5536):577–580. doi: 10.1038/258577a0. [DOI] [PubMed] [Google Scholar]
  41. Iversen L. L. Yet another opioid peptide? Nature. 1982 Oct 14;299(5884):578–579. doi: 10.1038/299578a0. [DOI] [PubMed] [Google Scholar]
  42. Janowsky D. S., Segal D. S., Bloom F., Abrams A., Guillemin R. Lack of effect on naloxone on schizophrenic symptoms. Am J Psychiatry. 1977 Aug;134(8):926–927. doi: 10.1176/ajp.134.8.926. [DOI] [PubMed] [Google Scholar]
  43. Jørgensen A., Fog R., Veilis B. Synthetic enkephalin analogue in treatment of schizophrenia. Lancet. 1979 Apr 28;1(8122):935–935. doi: 10.1016/s0140-6736(79)91426-0. [DOI] [PubMed] [Google Scholar]
  44. Jørgensen H. A., Cappelen C., Jr Naloxone-induced reduction of schizophrenic symptoms. Acta Psychiatr Scand. 1982 May;65(5):370–374. doi: 10.1111/j.1600-0447.1982.tb00858.x. [DOI] [PubMed] [Google Scholar]
  45. Kline N. S., Li C. H., Lehmann H. E., Lajtha A., Laski E., Cooper T. Beta-endorphin--induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry. 1977 Sep;34(9):1111–1113. doi: 10.1001/archpsyc.1977.01770210125012. [DOI] [PubMed] [Google Scholar]
  46. Krieger D. T. Brain peptides: what, where, and why? Science. 1983 Dec 2;222(4627):975–985. doi: 10.1126/science.6139875. [DOI] [PubMed] [Google Scholar]
  47. Kuhar M. J., Pert C. B., Snyder S. H. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973 Oct 26;245(5426):447–450. doi: 10.1038/245447a0. [DOI] [PubMed] [Google Scholar]
  48. Kurland A. A., McCabe O. L., Hanlon T. E., Sullivan D. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride. Am J Psychiatry. 1977 Dec;134(12):1408–1410. doi: 10.1176/ajp.134.12.1408. [DOI] [PubMed] [Google Scholar]
  49. LERNER A. B., CASE J. D., TAKAHASHI Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem. 1960 Jul;235:1992–1997. [PubMed] [Google Scholar]
  50. Lavond D. G., Mauk M. D., Madden J., 4th, Barchas J. D., Thompson R. F. Abolition of conditioned heart-rate responses in rabbits following central administration of [N-MePhe3, D-Pro4] morphiceptin. Pharmacol Biochem Behav. 1983 Aug;19(2):379–382. doi: 10.1016/0091-3057(83)90069-2. [DOI] [PubMed] [Google Scholar]
  51. Lehmann H., Nair N. P., Kline N. S. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects. Am J Psychiatry. 1979 Jun;136(6):762–766. doi: 10.1176/ajp.136.6.762. [DOI] [PubMed] [Google Scholar]
  52. Lewis R. V., Gerber L. D., Stein S., Stephen R. L., Grosser B. I., Velick S. F., Udenfriend S. On betaH-Leu5-endorphin and schizophrenia. Arch Gen Psychiatry. 1979 Feb;36(2):237–239. doi: 10.1001/archpsyc.1979.01780020127015. [DOI] [PubMed] [Google Scholar]
  53. Li C. H., Chung D. Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1145–1148. doi: 10.1073/pnas.73.4.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Lindström L. H., Widerlöv E., Gunne L. M., Wahlström A., Terenius L. Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states. Acta Psychiatr Scand. 1978 Feb;57(2):153–164. doi: 10.1111/j.1600-0447.1978.tb06883.x. [DOI] [PubMed] [Google Scholar]
  55. Lipinski J., Meyer R., Kornetsky C., Cohen B. M. Naloxone in schizophrenia: negative result. Lancet. 1979 Jun 16;1(8129):1292–1293. doi: 10.1016/s0140-6736(79)92247-5. [DOI] [PubMed] [Google Scholar]
  56. Lo C. W., Wen H. L., Ho W. K. Cerebrospinal fluid [Met5]enkephalin level in schizophrenics during treatment with naloxone. Eur J Pharmacol. 1983 Aug 19;92(1-2):77–81. doi: 10.1016/0014-2999(83)90110-3. [DOI] [PubMed] [Google Scholar]
  57. Madden J., 4th, Akil H., Patrick R. L., Barchas J. D. Stress-induced parallel changes in central opioid levels and pain responsiveness in the rat. Nature. 1977 Jan 27;265(5592):358–360. doi: 10.1038/265358a0. [DOI] [PubMed] [Google Scholar]
  58. Mains R. E., Eipper B. A. Differences in the post-translational processing of beta-endorphin in rat anterior and intermediate pituitary. J Biol Chem. 1981 Jun 10;256(11):5683–5688. [PubMed] [Google Scholar]
  59. Mains R. E., Eipper B. A., Ling N. Common precursor to corticotropins and endorphins. Proc Natl Acad Sci U S A. 1977 Jul;74(7):3014–3018. doi: 10.1073/pnas.74.7.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Mauk M. D., Madden J., 4th, Barchas J. D., Thompson R. F. Opiates and classical conditioning: selective abolition of conditioned responses by activation of opiate receptors within the central nervous system. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7598–7602. doi: 10.1073/pnas.79.23.7598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Mielke D. H., Gallant D. M. An oral opiate antagonist in chronic schizophrenia: a pilot study. Am J Psychiatry. 1977 Dec;134(12):1430–1431. doi: 10.1176/ajp.134.12.1430. [DOI] [PubMed] [Google Scholar]
  62. Minamino N., Kangawa K., Fukuda A., Matsuo H. Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides. 1984 Mar;4(2):157–166. doi: 10.1016/0143-4179(84)90126-4. [DOI] [PubMed] [Google Scholar]
  63. Naber D., Münch U., Wissmann J., Grosse R., Ritt R., Welter D. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist. Acta Psychiatr Scand. 1983 Apr;67(4):265–271. doi: 10.1111/j.1600-0447.1983.tb06740.x. [DOI] [PubMed] [Google Scholar]
  64. Naber D., Pickar D. The measurement of endorphins in body fluids. Psychiatr Clin North Am. 1983 Sep;6(3):443–456. [PubMed] [Google Scholar]
  65. Nakanishi S., Inoue A., Kita T., Nakamura M., Chang A. C., Cohen S. N., Numa S. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature. 1979 Mar 29;278(5703):423–427. doi: 10.1038/278423a0. [DOI] [PubMed] [Google Scholar]
  66. Nedopil N., Rüther E. Effects of the synthetic analogue of methionine enkephalin FK 33-824 on psychotic symptoms. Pharmakopsychiatr Neuropsychopharmakol. 1979 May;12(3):277–280. doi: 10.1055/s-0028-1094621. [DOI] [PubMed] [Google Scholar]
  67. Oyama T., Fukushi S., Jin T. Epidural beta-endorphin in treatment of pain. Can Anaesth Soc J. 1982 Jan;29(1):24–26. doi: 10.1007/BF03007943. [DOI] [PubMed] [Google Scholar]
  68. Oyama T., Jin T., Yamaya R., Ling N., Guillemin R. Profound analgesic effects of beta-endorphin in man. Lancet. 1980 Jan 19;1(8160):122–124. doi: 10.1016/s0140-6736(80)90606-6. [DOI] [PubMed] [Google Scholar]
  69. Oyama T., Matsuki A., Taneichi T., Ling N., Guillemin R. beta-Endorphin in obstetric analgesia. Am J Obstet Gynecol. 1980 Jul 1;137(5):613–616. doi: 10.1016/0002-9378(80)90706-1. [DOI] [PubMed] [Google Scholar]
  70. Pert C. B., Snyder S. H. Opiate receptor: demonstration in nervous tissue. Science. 1973 Mar 9;179(4077):1011–1014. doi: 10.1126/science.179.4077.1011. [DOI] [PubMed] [Google Scholar]
  71. Pethö B., Gráf L., Karczag I., Borvendég J., Bitter I., Barna I., Hermann I., Tolna J., Baraczka K. beta-Endorphin administration to acute schizophrenic patients: a double blind study. Ann N Y Acad Sci. 1982;398:460–469. doi: 10.1111/j.1749-6632.1982.tb39517.x. [DOI] [PubMed] [Google Scholar]
  72. Pfefferbaum A., Berger P. A., Elliott G. R., Tinklenberg J. R., Kopell B. S., Barchas J. D., Li C. H. Human EEG response to beta-endorphin. Psychiatry Res. 1979 Jul;1(1):83–88. doi: 10.1016/0165-1781(79)90031-3. [DOI] [PubMed] [Google Scholar]
  73. Pickar D., Davis G. C., Schulz S. C., Extein I., Wagner R., Naber D., Gold P. W., van Kammen D. P., Goodwin F. K., Wyatt R. J. Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry. 1981 Feb;138(2):160–166. doi: 10.1176/ajp.138.2.160. [DOI] [PubMed] [Google Scholar]
  74. Pickar D., Dubois M., Cohen M. R. Behavioral change in a cancer patient following intrathecal beta-endorphin administration. Am J Psychiatry. 1984 Jan;141(1):103–104. doi: 10.1176/ajp.141.1.103. [DOI] [PubMed] [Google Scholar]
  75. Pickar D., Vartanian F., Bunney W. E., Jr, Maier H. P., Gastpar M. T., Prakash R., Sethi B. B., Lideman R., Belyaev B. S., Tsutsulkovskaja M. V. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study. Arch Gen Psychiatry. 1982 Mar;39(3):313–319. doi: 10.1001/archpsyc.1982.04290030047009. [DOI] [PubMed] [Google Scholar]
  76. Port F. K., Kroll P. D., Swartz R. D. The effect of hemodialysis on schizophrenia: a survey of patients with renal failure. Am J Psychiatry. 1978 Jun;135(6):743–744. doi: 10.1176/ajp.135.6.743. [DOI] [PubMed] [Google Scholar]
  77. Risch S. C., Cohen R. M., Janowsky D. S., Kalin N. H., Murphy D. L. Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. Science. 1980 Sep 26;209(4464):1545–1546. doi: 10.1126/science.7433977. [DOI] [PubMed] [Google Scholar]
  78. Risch S. C. beta-Endorphin hypersecretion in depression: possible cholinergic mechanisms. Biol Psychiatry. 1982 Oct;17(10):1071–1079. [PubMed] [Google Scholar]
  79. Ross M., Berger P. A., Goldstein A. Plasma beta-endorphin immunoreactivity in schizophrenia. Science. 1979 Sep 14;205(4411):1163–1164. doi: 10.1126/science.472735. [DOI] [PubMed] [Google Scholar]
  80. Roth K. A., Weber E., Barchas J. D., Chang D., Chang J. K. Immunoreactive dynorphin-(1-8) and corticotropin- releasing factor in subpopulation of hypothalamic neurons. Science. 1983 Jan 14;219(4581):189–191. doi: 10.1126/science.6129700. [DOI] [PubMed] [Google Scholar]
  81. Sonders M., Barchas J. D., Weber E. Regional distribution of metorphamide in rat and guinea pig brain. Biochem Biophys Res Commun. 1984 Aug 16;122(3):892–898. doi: 10.1016/0006-291x(84)91174-4. [DOI] [PubMed] [Google Scholar]
  82. Sullivan S., Akil H., Blacker D., Barchas J. D. Enkephalinase: selective inhibitors and partial characterization. Peptides. 1980 Spring;1(1):31–35. doi: 10.1016/0196-9781(80)90032-7. [DOI] [PubMed] [Google Scholar]
  83. Tamminga C. A., Tighe P. J., Chase T. N., DeFraites E. G., Schaffer M. H. Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report. Arch Gen Psychiatry. 1981 Feb;38(2):167–168. doi: 10.1001/archpsyc.1981.01780270053006. [DOI] [PubMed] [Google Scholar]
  84. Tatemoto K., Mutt V. Chemical determination of polypeptide hormones. Proc Natl Acad Sci U S A. 1978 Sep;75(9):4115–4119. doi: 10.1073/pnas.75.9.4115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981 Sep 18;213(4514):1394–1397. doi: 10.1126/science.6267699. [DOI] [PubMed] [Google Scholar]
  86. Verhoeven W. M., van Praag H. M., van Ree J. M., de Wied D. Improvement of schizophrenic patients treated with [des-Tyr1]-gamma-endorphin (DTgammaE). Arch Gen Psychiatry. 1979 Mar;36(3):294–298. doi: 10.1001/archpsyc.1979.01780030060005. [DOI] [PubMed] [Google Scholar]
  87. Verhoeven W. M., van Ree J. M., Heezius-van Bentum A., de Wied D., van Praag H. M. Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients. Arch Gen Psychiatry. 1982 Jun;39(6):648–654. doi: 10.1001/archpsyc.1982.04290060010003. [DOI] [PubMed] [Google Scholar]
  88. Volavka J., Mallya A., Baig S., Perez-Cruet J. Naloxone in chronic schizophrenia. Science. 1977 Jun 10;196(4295):1227–1228. doi: 10.1126/science.860138. [DOI] [PubMed] [Google Scholar]
  89. Wagemaker H., Jr, Cade R. The use of hemodialysis in chronic schizophrenia. Am J Psychiatry. 1977 Jun;134(6):684–685. doi: 10.1176/ajp.134.6.684. [DOI] [PubMed] [Google Scholar]
  90. Wallace E. F., Evans C. J., Jurik S. M., Mefford I. N., Barchas J. D. Carboxypeptidase B activity from adrenal medulla--is it involved in the processing of proenkephalin? Life Sci. 1982 Oct 18;31(16-17):1793–1796. doi: 10.1016/0024-3205(82)90212-0. [DOI] [PubMed] [Google Scholar]
  91. Wallace E. F., Weber E., Barchas J. D., Evans C. J. A putative processing enzyme from Aplysia that cleaves dynorphin A at the single arginine residue. Biochem Biophys Res Commun. 1984 Feb 29;119(1):415–422. doi: 10.1016/0006-291x(84)91668-1. [DOI] [PubMed] [Google Scholar]
  92. Wang J. K., Nauss L. A., Thomas J. E. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979 Feb;50(2):149–151. doi: 10.1097/00000542-197902000-00013. [DOI] [PubMed] [Google Scholar]
  93. Watson S. J., Akil H., Berger P. A., Barchas J. D. Some observations on the opiate peptides and schizophrenia. Arch Gen Psychiatry. 1979 Jan;36(1):35–41. doi: 10.1001/archpsyc.1979.01780010041004. [DOI] [PubMed] [Google Scholar]
  94. Watson S. J., Akil H., Richard C. W., 3rd, Barchas J. D. Evidence for two separate opiate peptide neuronal systems. Nature. 1978 Sep 21;275(5677):226–228. doi: 10.1038/275226a0. [DOI] [PubMed] [Google Scholar]
  95. Watson S. J., Berger P. A., Akil H., Mills M. J., Barchas J. D. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects. Science. 1978 Jul 7;201(4350):73–76. doi: 10.1126/science.351804. [DOI] [PubMed] [Google Scholar]
  96. Watson S. J., Richard C. W., 3rd, Barchas J. D. Adrenocorticotropin in rat brain: immunocytochemical localization in cells and axons. Science. 1978 Jun 9;200(4346):1180–1182. doi: 10.1126/science.206967. [DOI] [PubMed] [Google Scholar]
  97. Watson S. J., Richard C. W., 3rd, Ciaranello R. D., Barchas J. D. Interaction of opiate peptide and noradrenalin systems: light microscopic studies. Peptides. 1980 Spring;1(1):23–30. doi: 10.1016/0196-9781(80)90031-5. [DOI] [PubMed] [Google Scholar]
  98. Weber E., Barchas J. D. Immunohistochemical distribution of dynorphin B in rat brain: relation to dynorphin A and alpha-neo-endorphin systems. Proc Natl Acad Sci U S A. 1983 Feb;80(4):1125–1129. doi: 10.1073/pnas.80.4.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Weber E., Esch F. S., Böhlen P., Paterson S., Corbett A. D., McKnight A. T., Kosterlitz H. W., Barchas J. D., Evans C. J. Metorphamide: isolation, structure, and biologic activity of an amidated opioid octapeptide from bovine brain. Proc Natl Acad Sci U S A. 1983 Dec;80(23):7362–7366. doi: 10.1073/pnas.80.23.7362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Weber E., Evans C. J., Barchas J. D. Acetylated and nonacetylated forms of beta-endorphin in rat brain and pituitary. Biochem Biophys Res Commun. 1981 Dec 15;103(3):982–989. doi: 10.1016/0006-291x(81)90906-2. [DOI] [PubMed] [Google Scholar]
  101. Weber E., Evans C. J., Barchas J. D. Predominance of the amino-terminal octapeptide fragment of dynorphin in rat brain regions. Nature. 1982 Sep 2;299(5878):77–79. doi: 10.1038/299077a0. [DOI] [PubMed] [Google Scholar]
  102. Weber E., Evans C. J., Chang J. K., Barchas J. D. Brain distributions of alpha-neo-endorphin and beta-neo-endorphin: evidence for regional processing differences. Biochem Biophys Res Commun. 1982 Sep 16;108(1):81–88. doi: 10.1016/0006-291x(82)91834-4. [DOI] [PubMed] [Google Scholar]
  103. Weber E., Roth K. A., Barchas J. D. Colocalization of alpha-neo-endorphin and dynorphin immunoreactivity in hypothalamic neurons. Biochem Biophys Res Commun. 1981 Dec 15;103(3):951–958. doi: 10.1016/0006-291x(81)90902-5. [DOI] [PubMed] [Google Scholar]
  104. Weber E., Roth K. A., Barchas J. D. Immunohistochemical distribution of alpha-neo-endorphin/dynorphin neuronal systems in rat brain: evidence for colocalization. Proc Natl Acad Sci U S A. 1982 May;79(9):3062–3066. doi: 10.1073/pnas.79.9.3062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Whitehouse P. J., Lynch D., Kuhar M. J. Effects of postmortem delay and temperature on neurotransmitter receptor binding in a rat model of the human autopsy process. J Neurochem. 1984 Aug;43(2):553–559. doi: 10.1111/j.1471-4159.1984.tb00934.x. [DOI] [PubMed] [Google Scholar]
  106. Zamir N., Weber E., Palkovits M., Brownstein M. Differential processing of prodynorphin and proenkephalin in specific regions of the rat brain. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6886–6889. doi: 10.1073/pnas.81.21.6886. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES